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Abstract
Chronic allograft vasculopathy (CAV) is an atheromatous-like lesion that affects vessels of transplanted organs. It is a
component of chronic rejection that conventional immuno-suppression fails to prevent, and is a major cause of graft loss.
Indirect allo-recognition through T cells and allo-Abs are critical during CAV pathogenesis. We tested whether the indirect
allo-response and its impact on CAV is down-regulated by in situ-delivery of donor Ags to recipient’s dendritic cells (DCs) in
lymphoid organs in a pro-tolerogenic fashion, through administration of donor splenocytes undergoing early apoptosis.
Following systemic injection, donor apoptotic cells were internalized by splenic CD11chi CD8a+ and CD82 DCs, but not by
CD11cint plasmacytoid DCs. Those DCs that phagocytosed apoptotic cells in vivo remained quiescent, resisted ex vivo-
maturation, and presented allo-Ag for up to 3 days. Administration of donor apoptotic splenocytes, unlike cells alive, (i)
promoted deletion, FoxP3 expression and IL-10 secretion, and decreased IFN-c-release in indirect pathway CD4 T cells; and
(ii) reduced cross-priming of anti-donor CD8 T cells in vivo. Targeting recipient’s DCs with donor apoptotic cells reduced
significantly CAV in a fully-mismatched aortic allograft model. The effect was donor specific, dependent on the physical
characteristics of the apoptotic cells, and was associated to down-regulation of the indirect type-1 T cell allo-response and
secretion of allo-Abs, when compared to recipients treated with donor cells alive or necrotic. Down-regulation of indirect
allo-recognition through in situ-delivery of donor-Ag to recipient’s quiescent DCs constitutes a promising strategy to
prevent/ameliorate indirect allorecognition and CAV.
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Introduction
Chronic rejection (CR) is a major problem in transplantation
that immuno-suppressive reagents fail to prevent and that limits
long-term allograft survival [1]. One of the key features of CR is
the development of chronic allograft vasculopathy (CAV), a
condition manifested by endothelialitis, intimal thickening, elastic
fiber disruption, adventitial fibrosis and leukocyte infiltration of
arteries of the graft [2]. As a consequence, the vessels undergo
progressive reduction of their lumen and become susceptible to
thrombosis [2]. CAV results form non-immune and immune
mechanisms, and lesions similar to CAV have been reproduced in
experimental models by adoptive transfer of allo-Abs or donor-
reactive PBMCs [3–5]. More recently, it has been shown that cells
of the innate immune system, including NK cells [6,7] and
macrophages [8] participate in the pathogenesis of CAV.
T cell recognize donor allo-peptides presented by recipient’s
APCs through the indirect pathway of allorecognition [9], a
mechanism that generates indirect pathway CD4 T cells and allo-
Abs, both critical in the pathogenesis of CAV [10–12] and CR
[13,14]. By using mice deficient in dendritic cells (DCs), we have
previously shown that recipient’s DCs are instrumental for
development of CAV [15]. However, besides their role in T cell
immunity, DCs resident in secondary lymphoid organs are critical
for induction of peripheral T cell tolerance in the steady-state [16],
a property that could be exploited therapeutically to restrain the
indirect alloresponse that leads to CAV [17].
The classic tolerogenic DC-based methods to down-regulate the
anti-donor response and prolong allograft survival are based on
administration of donor- or recipient-derived tolerogenic DCs
generated in vitro [reviewed in 18]. This first generation of DC-
therapies for transplantation has the following limitations for its
clinical application: (i) the time required for in vitro-generation of
DCs results a complication when the DCs have to be prepared
from deceased donors; (ii) the maturation of the injected DCs may
sensitize the recipient; (iii) injected DCs are re-processed by
recipient’s APCs; (iv) donor-derived DCs are targets of recipient’s
NK cells [19]; and (v) only a small percentage of the injected DCs
home in secondary lymphoid organs.
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An alternative DC-based method to control the indirect
alloresponse that leads to CAV consists in ‘‘in situ-delivery’’ of
donor allo-Ags to recipient’s DCs resident in secondary lymphoid
organs [17,18], without perturbing the quiescent state of the APCs
[20]. We and others [21–23] have shown that systemic
administration of leukocytes undergoing apoptosis constitutes
and efficient method to deliver foreign Ags to DCs in vivo,
without inducing DC activation. This is because cells in early
apoptosis (i) are processed efficiently by DCs and (ii) exert
regulatory effects on APCs [21–31]. Indeed, the apoptotic cell
clearance resulting from the physiological cell turnover in
peripheral tissues by DCs plays a key role in peripheral T cell
tolerance [32]. These observations have led to the recent
development of apoptotic cell-based strategies to promote
immunologic tolerance for therapy of transplantation and
autoimmunity. However, the mechanisms of action of apoptotic
cell-based therapies in vivo, their effects on different DC subsets in
vivo, and their therapeutic potential on chronic rejection
(currently one of the main problems in transplantation) have not
been elucidated.
In this study, we tested whether is situ delivery in a pro-
tolerogenic fashion of donor allo-Ags to recipient’s DCs by therapy
with apoptotic cells, down-regulates the indirect anti-donor
response and its effects on CAV. We characterized the DC
subsets targeted in vivo by this methodology and its impact on the
DCs and on allo-Ag presentation to indirect pathway T cells. Our
findings demonstrate that the features of CAV in a mouse model
of fully-mismatched aortic allografts (an established model of
CAV), are clearly ameliorated by in situ-targeting of DCs with
donor allo-Ags, and correlate with the ability of apoptotic cells,
unlike alive or necrotic cells, to restrain efficiently the anti-donor
indirect T and B cell responses in allograft recipients.
Materials and Methods
Mice and reagents
Ten-12-wk-old C57BL/6 (B6, H2b), BALB/c (H2d), C3H (H2k),
B66BALB/c (F1), b2 m
2/2 B6, and B6.FVB-Tg (Itagx-DTR/
eGFP)57Lan/J (CD11c-DTR-eGFP, H2
b) mice were from The
Jackson Laboratory. 1H3.1 and 2CRag12/2 TCRtg mice were
provided by Dr. C. Viret (Yale University) and Dr. G. Chalasani
(Univ. of Pittsburgh). Studies were approved by the IACUC.
FGK4.5 mAb was purchased from BIOExpress. PKH67,
histodenzTM, LPS, and diphtheria toxin (DT) were from Sigma.
The apoptosis detection kit was from BD Pharmingen. Mouse
rGM-CSF was from Peprotech. The IEa52–68 (ASFEAQGALA-
NIAVDKA) and SYGL (SIYRYYGL) peptides were synthesized,
HPLC-purified and confirmed by mass spectroscopy.
Generation of apoptotic and necrotic cells
Apoptotic splenocytes were generated by 3 min UV-B irradi-
ation with an UVB lamp (ULTRA-LUM, Claremont, CA, model
UVB16) [23]. The percentage of cells in early apoptosis (annexin
V+, propidium iodide2) reached 90–95% 3 h after irradiation,
with less than 5–10% of cells in late apoptosis. Necrotic
splenocytes were generated by 1 freeze-thaw cycle. BALB/c
splenocytes were stained with PKH67 before UV-irradiation or
freezing-thawing.
Purification and labeling of DCs
Spleens and thymi from B6 mice, untreated or injected with
PKH67+ apoptotic or necrotic BALB/c splenocytes, were flushed
with 100 U/ml collagenase and digested with 400 U/ml collage-
nase (30 min, 37uC). Cells were resuspended in cold Ca-free
0.01 M EDTA/HBSS and centrifuged over 16% histodenz
gradient. Splenic DC-enriched suspensions (20–30% DCs) were
blocked with 10% normal goat serum and incubated with the
following mAbs (BD Pharmingen, eBioscience): i) CyChrome
(CyC)-CD11c; ii) PE-H2Kb, -IAb, -CD40, -CD45RA, -CD80, -
CD86, -ICOSL, -CD178 (FasL), -PD-L1 or -PD-L2; and iii) APC-
CD8a. Species- and isotype-matched Igs were used as controls.
Cells were fixed in 2% paraformaldehyde and analyzed with a BD
FACSCaliburTM flow cytometer (BD Biosciences). Liver nonpar-
enchymal cells were purified as described [33].
Adoptive transference of TCRtg T cells
1H3.1 CD4 T cells (Thy1.1 congenic) were purified from
spleens and lymph nodes by depleting CD8, B220, IAb, F4/80 and
NK1.1-expressing cells (DynabeadsH). 1H3.1 cells were labeled or
not with 5 mM CFSE (Molecular Probes) and 36106 cells were
administered i.v. to WT or CD11c-DTR-eGFP B6 mice. In some
experimental groups, mice were injected with DT (4 ng/g body
weight, i.p.). One day later, animals received i.v. 107 BALB/c
splenocytes alive or apoptotic, the latter alone or with agonistic
CD40 mAb (FGK4.5; 150 mg; i.p.; on days 1–3). As control, B6
mice were injected with 107 B6 apoptotic splenocytes alone. Three
and 14 days later, cells from spleens and lymph nodes (inguinal,
axilar, cervical, mesenteric) were stained with the following mAbs:
i) CyC-CD4; ii) PE-CD62L, -CD69 or -FoxP3; and iii) APC-
Thy1.1. Species- and isotype-matched Igs were used as controls.
Cells were fixed in 2% paraformaldehyde and FACS-analyzed.
In vivo killing assay
B6 (H2Kb) mice, reconstituted with 2C CD8 T cells (26106
cells/ i.v.), were treated (i.v.) the following day with apoptotic or
alive b2 m
2/2 B6 splenocytes pre-loaded (or not, control) in vitro
with the SYGL peptide (1 mg/ml, 3 h, 37uC). Six days later, mice
were challenged (or not, control) with 25 mg of SYGL peptide in
incomplete Freund adjuvant (IFA, 200 ml, i.p.). Three days later,
mice received a 1:1 mixture of target B66BALB/c splenocytes
labeled with 5 mM CFSE (CFSEhi), and control B6 splenocytes
labeled with 0.5 mM CFSE (CFSElo) (26107 total cells in 300 ml
PBS / mouse). Five h later, the percentages of splenic CFSEhi and
CFSElo cells was assessed by FACS. Percent specific lysis was
calculated by the formula: {12[(ratio of CFSElo/CFSEhi of naive
mouse) / (ratio of CFSElo/ CFSEhi of challenged mouse)]}6100.
ELISPOT and allo-Ag proliferation assays
For ELISPOT analysis of 1H3.1 T cells, splenocytes of host B6
mice [reconstituted with 1H3.1 CD4 T cells and then treated with
BALB/c (or B6, control) apoptotic, necrotic or living splenocytes]
were incubated with (or without, control) 1 mg/ml IEa52–68, in 96-
well ELISPOT plates (BD Biosciences) coated with IFN-c, IL-4,
IL-10, IL-17 or TGF-b1 mAbs (2.56105 cells/ well). ELISPOT
plates were cultured for 36 h followed by incubation with biotin-
IFN-c, -IL-4, -IL-10, -IL-17 and -TGF-b1 mAbs, streptavidin-
peroxidase and 3-amino-9-ethylcarbazole (AEC). The spots were
counted with an ImmunoSpotTM counter (Cellular Technology
Ltd., Cleveland, OH). For allo-Ag proliferation assays of 1H3.1 T
cells, splenocytes were incubated with (or without, control) 1 mg/
ml IEa52–68 in round-bottom 96-well plates (2.5610
5 cells /well).
Cell proliferation was evaluated 72 h later by assessment of
[3H]thymidine incorporation.
For ELISPOT analysis of the indirect response in graft recipients,
purified splenic T cells (enrichment columns, R&D Systems) from
B6 mice transplanted with syngeneic or BALB/c aortas were
incubated with CD3-depleted, c-irradiated, splenic B6 APCs
(36105 T cells and 2.56106 APCs / well) and 20 ml of sonicates
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prepared from BALB/c, B6 or C3H splenocytes, in 96-well
ELISPOT plates coated with IFN-c mAb [34]. For ELISPOT
analysis of the direct response, purified splenic T cells (enrichment
columns, R&D Systems) from B6 mice transplanted with syngeneic
or BALB/c aortas were incubated with CD3-depleted, c-irradiated,
splenic BALB/c, B6 or C3H APCs (56104 T cells and 2.56105
APCs / well) in 96-well ELISPOT plates coated with IFN-c mAb.
Aortic transplantation
Intra-abdominal aortic transplantation was performed as
described [35]. A 6–10 mm segment of the donor’s descending
thoracic aorta was anastomosed (end to side) to the recipient’s
abdominal aorta. The native abdominal aorta was then ligated
and severed, converting the end-to-side anastomosis to a quasiend-
to-end anastomosis.
Figure 1. Blood-borne donor apoptotic cells are captured and presented to T cells by splenic CD11chi DCs. A) PKH67-labeled BALB/c
apoptotic cells were injected i.v. in B6 mice and the entrapment of blood-borne PKH-67+ (green) apoptotic cell fragments by splenic CD11chi
CD45RA2 DCs (CD8a+ or CD8a2) and CD11cint CD45RA+ pDCs was analyzed by FACS, 18 h later. B) WT and CD11c-DTR-eGFP B6 mice (both Thy1.2+)
were reconstituted with CFSE-labeled 1H3.1 CD4 T cells (Thy1.1+), then treated (or not, control) with DT and injected i.v. with BALB/c apoptotic cells.
Injection of DT in CD11c-DTR-eGFP mice deleted selectively CD11chi DCs and spared CD11cint pDCs in the spleen (upper dot plots). In the absence of
splenic pDCs, CD11c-DTR-eGFP mice were unable to present BALB/c apoptotic cell-derived allopeptides and induce proliferation of the adoptively
transferred 1H3.1 CD4 T cells, evaluated 48 h later by CFSE-dilution by FACS-analysis (bottom dot plots). One representative out of 5 (in A) and 3 (in B)
individual experiments is shown.
doi:10.1371/journal.pone.0004940.g001
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Figure 2. Splenic DCs remain quiescent following interaction with donor apoptotic cells in vivo. A) B6 mice were left untreated or
injected i.v. with PKH67-labeled BALB/c apoptotic splenocytes. Histograms show the expression of surface markers by splenic CD11chi DCs (i) with
internalized PKH-67+ apoptotic cell fragments (thick line), (ii) without PKH-67+ fragments from the same mice (gray), and (iii) from control non-
injected mice (dotted line). One representative out of 3 individual experiments is illustrated. B) Eighteen h after i.v. administration of PKH-67-labeled
BALB/c apoptotic splenocytes in B6 mice, splenic CD11chi DCs with internalized PKH-67+ fragments (R2) or not (R1) were FACS-sorted and cultured in
medium with GM-CSF and LPS. After 24 h, surface expression of MHC class-II Ag and CD86 was analyzed by flow cytometry in the FACS-sorted splenic
DCs that had internalized PKH-67+ fragments (gray histograms) or not (thick line histograms), and compared to the phenotype of freshly-isolated
splenic CD11chi DCs (dotted line histogram). One representative out of 3 experiments is shown. C) CFSE-labeled 1H3.1 CD4 T cells were adoptively
transferred (i.v.) into B6 mice at different times after administration of BALB/c splenocytes (alive, apoptotic or necrotic) and proliferation of 1H3.1 T
Apoptotic Cells & Vasculopathy
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Analysis of aortic grafts
Aortic grafts were harvested 1 mm beyond the sutures and
divided into two equal segments. One fragment was fixed in 4%
paraformaldehyde, processed and cross-sectioned for staining with
H&E, Verhoeff-van Gieson’s (elastic fibers), Masson’s trichrome
(collagen) and immunoperoxidase for a-smooth muscle (a-sm)
actin+ cells. Sections were blocked with 10% normal goat serum
and incubated with a-sm actin mAb (Dako-1A4), biotin-
secondary Ab and the final product visualized with the ABC
immunoperoxidase system with the substrate AEC (Vector). The
other half of the graft was embedded in Tissue-Tek OCT (Miles
Laboratories), snap-frozen, and stored at280uC. Cryostat sections
(6 mm) were air-dried, fixed in 96% ethanol, and blocked with
10% normal goat serum and the avidin/biotin blocking kit
(Vector). For detection of CD4 together with CD8 or FoxP3,
sections were incubated with alexa 488-CD4 and biotin-CD8 or
biotin-FoxP3 mAbs followed by Cy3-streptavidin. For co-detection
of IgG and C3d, sections were incubated with 2-fold dilutions
(1:25–1:400) of alexa 488 anti-mouse IgG (Molecular Probes) and
biotin C3d (1:100) mAbs (R&D), followed by streptavidin-Cy3.
Nuclei were stained with DAPI (Molecular Probes). IgG deposition
was assessed semi-quantitatively by determination of the end-titer
dilution of the anti-mouse IgG mAb. Sections were analyzed with
a fluorescence microscope (Zeiss) equipped with an imaging system
and the image analyzing software Axio Vision.
Detection of alloantibodies
Sera allo-Abs were FACS-analyzed in naı¨ve B6 and in B6 mice
transplanted with syngeneic or BALB/c aortas. BALB/c spleno-
cytes were incubated with a 1:10 dilution of de-complemented
sera. Cells were then incubated with PE-CD19 mAb and one of
the following FITC-mAbs: i) F(ab9)2 anti-mouse Fcc (Jackson
ImmunoResearch); ii) anti-mouse IgG1; or iii) anti-mouse IgG2a
(BD Pharmingen).
Statistical analyses
Results are expressed as means6SD. Comparisons between
more than 2 means were performed by ANOVA, followed by the
Student Newman Keuls test. Comparison between two means was
performed by Student’s ‘‘t’’ test. A ‘‘p’’ value,0.05 was considered
significant.
Results
Donor apoptotic cells administered systemically are
presented by CD11chi DCs
The following subsets of DCs coexist in mouse secon-
dary lymphoid organs: i) CD11chiCD82 DCs (myeloid); ii)
CD11chiCD8a+ DCs (lymphoid-related) and iii) CD11cintC-
D45RA+ B220+Gr1+ plasmacytoid DCs (pDCs) [36]. We and
others have shown in mice that (i) blood-borne leukocytes
undergoing apoptosis are captured by splenic CD11chi DCs [21–
23], and (ii) in situ-delivery of allo-Ags to splenic DCs by i.v.
injection of donor apoptotic cells down-regulates anti-donor T cell
immunity, prolongs cardiac allograft survival [37,38] and
facilitates BM engraftment [39–41]. Although CD11cint pDCs
also play an important role in down-regulating the T cell response
[42–44] and likely in transplantation tolerance [45–47], their
ability to interact with apoptotic cells is still controversial [48–51].
Thus, we assessed in vivo the ability of recipient’s pDCs to capture
donor apoptotic cells administered systemically, and the role of
pDCs in the beneficial effect of apoptotic cell therapy in
transplantation.
To address this question, PKH67-labeled (green) UVB-induced
early apoptotic BALB/c splenocytes were injected i.v. in B6 mice
(107cells / mouse). Since the highest percentages of splenic DCs
with internalized allogeneic apoptotic cells are detected 18–24 h
after i.v. injection [23], we analyzed by FACS the percentages of
splenic DC subsets containing PKH67+ apoptotic cell fragments,
18 h after apoptotic cell administration. As expected [23], 1866%
of CD11chi DCs (6064% CD8a+ and 3966% CD8a2 DCs)
contained PKH67+ fragments (Fig. 1A). By contrast, we did not
detect PKH67+ content within CD11cint CD45RA+ pDCs
(Fig. 1A). Less than 1% of CD11chi DCs and no pDCs from
lymph nodes, thymus and liver internalized the injected apoptotic
cells (not shown). Necrotic PKH67+ BALB/c splenocytes were
very poorly or no internalized by spleen, thymus, lymph node or
liver CD11chi DCs (#2%) or CD11cint pDCs (#0.01%) (not
shown).
To further confirm that pDCs were unable to process and
present Ags derived from donor apoptotic cells, we tested if B6
splenic pDCs present the BALB/c apoptotic cell-derived allopep-
tide IEa52–68 to CFSE-labeled Thy1.1 congenic 1H3.1 TCRtg
CD4 T cells [specific for IAb (from B6)-IEa52–68, 52]. To assess the
role of pDCs, we used as hosts B6 CD11c-DTR-eGFP mice
(Thy1.2 congenic), a DT receptor (DTR)-based system where
CD11chi DCs can be conditionally ablated for up to 2–3 days by
administration of DT [53], whereas CD11cint pDCs are spared
from deletion [54]. Forty eight h after injection of BALB/c
apoptotic cells into B6 CD11c-DTR-eGFP mice, we detected
proliferation of splenic 1H3.1 cells, assessed by CFSE-dilution
analyzed by FACS (Fig. 1B). B6 CD11c-DTR-eGFP mice treated
with DT exhibited almost complete deletion of CD11chi DCs with
preservation of CD11cint pDCs and no proliferation of splenic
1H3.1 cells (Fig. 1B). The lack of division of 1H3.1 cells was not
due to the DT, since 1H3.1 cells proliferated in WT B6 mice
injected with BALB/c apoptotic cells and DT (Fig. 1B). These
findings indicate that only splenic CD11chi DCs capture and
process blood-borne donor apoptotic cells for presentation to
indirect CD4 T cells.
DCs that internalize apoptotic cells in vivo remain
quiescent and resistant to maturation
There is evidence that DCs that internalize apoptotic cells fail to
upregulate MHC Ag, CD40, CD80 and CD86 in vitro [23–30]
and in vivo [37]. However, it is unknown whether this
phenomenon also affects the expression of immune–regulatory
molecules like PDL-1, PDL-2, ICOS-L and Fas-L. To address this,
B6 mice were injected with PKH67+ BALB/c apoptotic cells and
the phenotype of splenic CD11chi DCs was analyzed in DC-
enriched suspensions by FACS, 6, 24 and 48 h later, time points
when the DCs should be interacting with Ag-specific T cells.
Internalization of PKH-67+ apoptotic cell fragments did not affect
expression of MHC-I/II, CD40, CD54, CD86, PD-L1, PD-L2,
and ICOS-L, and induced a modest up-regulation of CD80 and
Fas-L (CD178) in splenic CD11chi DCs, compared with DCs
without apoptotic cells from the same animal, or with DCs from
non-injected controls (Fig. 2A, 24 h).
cells was evaluated based on CFSE dilution assessed by FACS, 3 days after T cell transference. Presentation of BALB/c allopeptides to splenic 1H3.1
CD4 T cells (based on CFSE-dilution) decreased drastically by 7 days. Numbers represent percentages of dividing cells. One representative experiment
with 3 mice per group and time point is shown.
doi:10.1371/journal.pone.0004940.g002
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Next, we tested whether splenic CD11chi DCs that internalize
donor apoptotic cells in vivo are resistant to maturation. Eighteen
h after i.v. administration of PKH67+ BALB/c apoptotic cells in
B6 mice, splenic CD11chi DCs that had internalized (PKH67+) or
not (PKH672) apoptotic cells were FACS-sorted and cultured for
24 h in medium with GM-CSF (1000 u/ml) and LPS (100 ng/ml)
(Fig. 2B). Unlike control splenic DCs without apoptotic cells, DCs
that had phagocytosed apoptotic cells in vivo (from the same mice)
failed to up-regulate MHC-II Ag and CD86 ex vivo in response to
overnight stimulation with LPS (or 5 mg/ml of agonistic CD40
mAb, not shown) (Fig. 2B). DCs with internalized apoptotic cells
did not exert a bystander inhibition on the phenotype of those
DCs that did not contain apoptotic cell fragments, since the latter
DCs expressed levels of MHC-II Ag and CD86 comparable to
those of splenic DCs freshly-isolated from control mice not treated
with apoptotic cells (Fig. 2B). Thus, following internalization of
apoptotic cells in vivo, splenic DCs remained quiescent, without
altering their net balance of co-stimulatory/-regulatory molecules,
failed to mature ex vivo, and did not exert bystander inhibitory
effects on the phenotype of neighboring DCs without apoptotic
cell fragments.
Splenic DCs present apoptotic cell-derived allopeptides
for a limited time-span
We assessed the duration of presentation of apoptotic cell-
derived allopeptides by splenic DCs in B6 mice injected with
BALB/c apoptotic cells, 28, 14, 7, 3 and 1 day prior to adoptive
transference of CFSE-labeled 1H3.1 CD4 T cells (day 0). Three
days after 1H3.1 cell transfer, proliferation of splenic 1H3.1 T cells
was evaluated by FACS-analysis. As controls, B6 mice were
injected i.v. with the same numbers of alive or necrotic BALB/c
splenocytes. Presentation of the apoptotic cell-derived IEa52–68
allopeptide to 1H3.1 T cells reached a plateau 3 days after
apoptotic cell administration, decreased by day 7 (Fig. 2C), and
was undetectable thereafter. Although unlike apoptotic cells,
necrotic cells promotes maturation of DCs [26,27], we detected
minimum proliferation of splenic 1H3.1 T cells in vivo following
infusion of necrotic BALB/c splenocytes (Fig. 2C). This latter
result can be explained by the fact that systemically administered
necrotic cells were very poorly internalized by splenic DCs.
Effect of in situ-targeting of splenic DCs on indirect
pathway CD4 T cells
We investigated whether in situ-targeting of DCs with donor
apoptotic cells affects the anti-donor response elicited by indirect
pathway CD4 T cells, and if the effect differs from that induced by
donor splenocytes alive. B6 mice, reconstituted with CFSE-labeled
naı¨ve (CD62Lhi CD44lo) 1H3.1 CD4 T cells, were injected i.v.
with BALB/c splenocytes alive or apoptotic the following day. As
positive control of T cell activation, a group received BALB/c
apoptotic cells plus agonistic CD40 mAb. Infusion of BABL/c
splenocytes, alive or apoptotic, induced proliferation of splenic
1H3.1 cells assessed 3 days later by FACS-analysis (Fig. 3A).
Unlike apoptotic cells, injection of cells alive was accompanied by
division of 1H3.1 T cells in lymph nodes (not shown), a difference
that can be explained because living cells migrate actively through
all lymphoid organs, whereas apoptotic cells mobilize passively
through circulation, from where they are captured by marginal
zone phagocytes [23].
In mice injected with cells alive (3 days before), proliferating
1H3.1 CD4 T cells in the spleen up-regulated CD69 and reduced
CD62L expression (Fig. 3A), although to a lower extent than the
positive controls of T cell activation. Interestingly, in B6 mice that
received BALB/c apoptotic cells, proliferating 1H3.1 T cells did
not increase CD69 nor down-regulate CD62L (Fig. 3A), and when
re-stimulated with IEa52–68 ex vivo contained a significantly lower
frequency of IFN-c-secreting cells compared to animals treated
with cells alive or with apoptotic cells plus CD40 mAb (Fig. 3B).
We did not detect differences in the percentages of CD4 FoxP3+
1H3.1 cells (#2%, by FACS), or the number of IL-4-, IL-10-, IL-
17- or TGF-b1-secreting cells in response to IEa52–68 (#25 spots/
106 splenocytes, by ELISPOT, not shown), between splenocytes
B6 mice injected 3 days before (or not, controls) with BALB/c
splenocytes alive or apoptotic.
The initial expansion in the percentage of splenic 1H3.1 T cells
detected at day 3 in B6 mice treated with BALB/c cells alive or
apoptotic, was followed at day 14 by a severe reduction in the
number of 1H3.1 cells in mice treated with apoptotic cells
(Fig. 3C). The finding that the percentage of 1H3.1 T cells in the
lungs was lower (p,0.01) in mice treated with apoptotic cells
compared to controls under CD40 stimulation or mice treated
with cells alive, suggests that deletion instead of homing to
periphery, was the cause of the reduction in the number of 1H3.1
T cells in mice that received apoptotic cells (Fig. 3C). At day 14,
proliferation and the percentage of IFN-c-secreting of 1H3.1 T
cells in the spleen was lower (p,0.01) in mice injected with
apoptotic splenocytes compared to animals treated with cells alive
or to positive controls stimulated via CD40 (Fig. 4A). Interestingly,
at day 14, B6 mice treated with BALB/c apoptotic cells exhibited
an increase (p,0.01) in the percentage of splenic 1H3.1 T cell
secreting IL-10 in response to IEa52–68 re-stimulation (Fig. 4A),
and an augment in the percentage of FoxP3+ 1H3.1 T cells
(Fig. 4B). In summary, systemic injection of donor apoptotic
splenocytes, unlike donor cells alive, affects severely the develop-
ment of type-1 indirect pathway CD4 T cells.
Effect of apoptotic cell therapy on cross-priming of anti-
donor CD8 T cells
Next, we tested if administration of apoptotic cells affects cross-
priming of donor-reactive CD8 T cells in vivo. B6 mice,
reconstituted with 2C TCRtg CD8 T cells (specific for SYGL-
H2Kb) [55], were treated the following day with apoptotic or alive
b2 m
2/2 B6 splenocytes loaded in vitro with SYGL peptide (107
cells/ i.v.). Since these latter cells lack surface MHC class-I, the
only mechanism by which the SYGL-H2Kb complex can be
Figure 3. Donor apoptotic cells are recognized by indirect CD4 T cells. A) Analysis by FACS of proliferation and phenotype of CFSE-labeled
1H3.1 CD4 T cells transferred into B6 mice that were then treated (i.v.) with BALB/c splenocytes, alive or apoptotic. As control, to promote 1H3.1 T cell
activation/proliferation, a group of B6 mice was treated with BALB/c apoptotic cells plus agonistic CD40 mAb. Numbers in dot plots represent
percentages of cells. Numbers in parenthesis indicate the mean fluorescence intensity of the left quadrants combined. One representative
experiment out of 6 is shown. B) ELISPOT analysis for IFN-c of splenocytes from B6 mice reconstituted (or not, control) with 1H3.1 CD4 T cells and
then injected i.v. with B6 (control) or BALB/c apoptotic splenocytes (alone or with agonistic CD40 mAb), or with BALB/c splenocytes alive. Three days
later, splenocytes from the host B6 mice were cultured for 36 h in ELISPOT plates alone, or with the BALB/c peptide IEa52–68. Each group included 6
mice. C) Assessment by FACS of the percentages of CD4 1H3.1 T cells (Thy1.1+) in tissues of host B6 mice (Thy1.2+) previously reconstituted with
1H3.1 cells and then treated with B6 (control) or BALB/c apoptotic splenocytes (the latter alone or with agonistic CD40 mAb), or with BALB/c
splenocytes alive. Results represented values pooled from 6 mice per group. * p,0.01.
doi:10.1371/journal.pone.0004940.g003
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Figure 4. Administration of donor apoptotic cells regulates the indirect T cell responses. A) Allo-Ag presentation and ELISPOT assays of
splenocytes from B6 mice reconstituted (or not, control) with 1H3.1 CD4 T cells and then injected i.v. with B6 (control) or BALB/c apoptotic
splenocytes (alone or with agonistic CD40 mAb), or with BALB/c splenocytes alive. Fourteen days later, splenocytes from the host B6 mice were
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presented to 2C cells is through cross-priming by host’s B6 (H2Kb)
APCs. After 6 days, B6 mice were challenged with SYGL peptide
(plus IFA, i.p.), and three days later (day 9) the function of the
transferred 2C cells was assessed by 5 h-in vivo killing assays.
Given that our transplant model employs the BALB/c (donor)R
B6 (recipient) combination, we selected B66BALB/c (F1) spleno-
cytes as targets, since (i) 2C cells also recognize H2Ld molecules
(from BALB/c) (55), and (ii) the presence of ‘‘self-MHC molecules’’
(from B6) prevents killing of the target cells by host’s NK cells.
Administration of b2 m
2/2 B6 apoptotic cells loaded with SYGL
decreased the Ag-specific lytic activity of splenic 2C cells, when
compared to controls that received apoptotic cells not exposed to
the peptide (1064 vs. 77610% lysis, respectively, p,0.001)
(Fig. 4C). This inhibitory effect was reversed by co-administration
of agonistic CD40 mAb by the time of apoptotic cell infusion
(6768% lysis), and was not achieved by administration of the same
number of b2 m
2/2 B6 living splenocytes pulsed with SYGL
(6367% lysis) (Fig. 4C).
Impact on development of CAV of in situ delivery of
donor alloAg to recipient’s DCs
Next, we tested the effect of targeting in situ recipient’s splenic
DCs with donor apoptotic cells on development of CAV in a
model of aortic allografts. B6 recipient mice were injected (i.v., d-
7) with 107 BALB/c apoptotic splenocytes, and then transplanted
with BALB/c aortas. Controls included B6 mice untreated, or
injected with BALB/c (donor) alive or necrotic, or C3H (third-
party) apoptotic splenocytes (6 mice per group, Fig. 5A). The
aortic allografts were examined 60 days after transplantation.
No histopathological changes were detected in control BALB/c
aortas transplanted in syngeneic recipients and were indistinguish-
able from native BALB/c aortas (Fig. 5A). BALB/c aortic grafts
transplanted in untreated B6 mice showed severe signs of CAV,
including: (i) diffuse intimal thickening comprising the entire
circumference of the artery and caused mainly by infiltration of a-
sm actin+ cells; (ii) partial fragmentation and thickening of the
internal elastic membrane; (iii) deposition of collagen; and (iv)
infiltration by CD4 and CD8 T cells (Fig. 5A–C and Fig. 6).
Compared to allografts from untreated mice, BALB/c aortas from
B6 recipients treated with donor apoptotic cells exhibited the
following features: (i) significant reduction of intimal thickening
(p,0.001); (ii) minimum infiltration of a-sm actin+ cells; (iii) no
damage of the elastic fibers; (iv) substantial reduction in the
amount of collagen deposition; and (v) decreased number of
infiltrating CD8 and CD4 T cells (Fig. 5A–C and Fig. 6). We did
not detect CD4 Foxp3+ T cells within the allografts.
The beneficial effect of donor apoptotic cells on CAV was
dependent on the intrinsic properties of the apoptotic cells, since
the histopathology of aortic allografts from controls treated with
donor splenocytes alive or necrotic was similar to that of untreated
mice (Fig. 5A). The effect of apoptotic cell therapy on CAV was
donor-specific, since injection of third-party (C3H) splenocytes in
early apoptosis did not have a significant effect on the parameters
of CAV analyzed (Fig. 5A).
The beneficial effects of donor apoptotic cells on CAV are
associated to down-regulation of the anti-donor
response
We hypothesized that presentation of donor alloAgs by
recipient’s quiescent DCs controls the indirect anti-donor
response, key in the pathogenesis of CAV [10–12]. Therefore,
we assessed the effect of donor apoptotic cell therapy on the
indirect T cell response, 60 days after transplantation of BALB/c
aortas in B6 recipients. The frequency of responder splenic T cells
(purity $96%) secreting IFN-c following stimulation with splenic
B6 APCs plus sonicates from BALB/c (donor), C3H (third-party)
or B6 (syngeneic) splenocytes was evaluated by ELISPOT. The
frequency of spots for IFN-c was significantly reduced (p,0.001)
in recipients that received donor apoptotic cells, when compared
to mice left untreated or injected with BALB/c splenocytes alive or
necrotic, or with C3H apoptotic cells (Fig. 7A). Responder T cells
did not release IFN-c when incubated with BALB/c sonicates
alone, indicating that the sonicates were sufficiently disrupted to
prevent any direct allorecognition, and that there were not
residual recipient’s APCs in the purified responder T cells.
Since delivery of donor alloAgs to recipient’s DCs in vivo with
donor apoptotic cells down-regulated the indirect T cell response,
we next tested if this mechanism also affected the downstream
cognate interaction between indirect Th cells and donor-reactive B
cells, and the subsequent production of allo-Abs. Sixty days after
aortic transplantation, recipients treated with donor apoptotic
splenocytes decreased drastically the levels of circulating total IgG
(Fig. 7B), IgG1 and IgG2a (not shown) allo-Abs. The reduction in
the levels of allo-Abs in sera of recipients treated with donor
apoptotic cells was not caused by deposition of the allo-Abs in the
grafts. Microscopic analysis demonstrated that aortic allografts
from recipients treated with donor apoptotic cells exhibited
considerably lower amounts of locally deposited IgG (end-titer
1:25) and C3d compared to grafts from recipients untreated (IgG
end-titer 1:400), or injected with BALB/c splenocytes alive (IgG
end-titer 1:400) or necrotic (IgG end-titer 1:200).
Next, we analyzed if therapy with donor apoptotic cells affected
the direct T cell response. Sixty days after transplantation of
BALB/c aortas, the frequency of (B6) splenic T cells secreting
IFN-c in response to splenic BALB/c, B6 or C3H APCs was
assessed by ELISPOT. Administration of donor apoptotic cells
decreased significantly (p,0.001) the type-1 direct T cell response
compared to controls, in a donor-specific fashion, as demonstrated
by the direct response against third-party (C3H) APCs (Fig. 7C).
Discussion
In the present study, we demonstrated that delivery of donor
allo-Ags to recipient’s DCs in situ is an efficient approach to
control the indirect anti-donor response that contributes to CAV,
cultured alone or with the BALB/c peptide IEa52–68 during 72 h for assessment of T cell proliferation by [
3H]TdR incorporation, or for 36 h in ELISPOT
plates for quantification of IFN-c and IL-10 secretion. Each group included 6 mice. B) Analysis by FACS of the percentage of CD4 1H3.1 T cells
(Thy1.1+) expressing FoxP3 in the spleen of host B6 mice (Thy1.2+) 14 days after receiving i.v. B6 (control) or BALB/c apoptotic splenocytes, or BALB/c
splenocytes alive. Numbers indicate percentages of cells. One representative of 6 individual experiments is shown. * p,0.01. C) Assessment by in
vivo killing assays of the Ag-specific lytic activity of B6 mice reconstituted with 2C CD8 T cells and treated (day 1) with 107 MHC-I2/2 B6 apoptotic or
alive splenocytes loaded (or not) with the H2Kb-retricted SYGL peptide. Mice were challenged (or not) on day 6 with SYGL plus IFA (i.p.). On day 9,
mice were i.v. injected with a 1/1 mixture of CFSEhi BALB/c6B6 (F1) (target) and CFSElo B6 (control) splenocytes. Five h later, the ratio of CFSEhi vs.
CFSElo cells in the spleen was determined by FACS. Numbers indicate percentages of cells. The specific lysis was calculated and is shown as the
mean6SD of 3 mice per group.
doi:10.1371/journal.pone.0004940.g004
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Figure 5. Effect of donor apoptotic splenocytes on CAV. A) Microscopic analysis of cross-sections of aortic BALB/c grafts procured 60 days
after transplantation from syngeneic or allogeneic (B6) recipient mice left untreated, or injected (i.v., day -7) with BALB/c splenocytes apoptotic,
necrotic or alive, or with C3H (third-party) apoptotic splenocytes. Sections were stained with H&E or to identify collagen deposition, elastic fibers, or
a-sm actin+ cells. The sections shown are representative of 6 independent aortic transplants per group. B) Method employed to quantify
morphometrically intimal thickening in aortic grafts by means of a microscope equipped with an imaging system and image analyzing software. C)
Comparison of the intimal thickening of aortic BALB/c grafts, 60 days after transplantation in syngeneic or B6 recipient mice left untreated or injected
with BALB/c splenocytes apoptotic, necrotic, or alive, or with C3H (third-party) apoptotic splenocytes. Results represented values pooled from 6 mice
per group.
doi:10.1371/journal.pone.0004940.g005
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a key component of CR. Previous studies have shown the
possibility of down-regulating the T cell response by delivering
model Ags to quiescent DCs resident in secondary lymphoid
organs [56–59]. In mice, this have been accomplished by
administration of antigenic peptides linked to CD205-mAb, which
recognizes the lectin DEC205 expressed by DCs of T cell areas in
secondary lymphoid organs [56–59]. For transplantation, this
elaborated technique may result impractical for in situ-delivery of
the entire repertoire (or only the immuno-dominant) allo-peptides
to recipient’s DCs, due to haplotype variability in each donor-
recipient combination. In recent years, delivery of donor allo-Ags
to recipient DCs is situ has been achieved by administration of
apoptotic cells [23,37,38] or DC-derived exosomes [60].
A complication to investigating the impact of delivery of foreign
Ag to DCs in vivo and the resulting outcome on the T cell
response is the existence of different DC subsets whose roles in
peripheral tolerance are still unclear. pDCs could potentially
mediate the regulatory effect of donor apoptotic cells on anti-
donor T cells, since they facilitate transplantation tolerance in
mice [45–47]. However, previous studies have not addressed the
role of pDCs in the regulation of the T cell response that follows
apoptotic cell therapy, and the capability of pDCs to phagocytose
apoptotic cells is still controversial. Dalgaard et al. [48] have
demonstrated that pDCs are unable to phagocytose apoptotic
cells, whereas others have shown that pDCs internalize fluoro-
chromes, latex beads, immuno-complexes and virus-infected
apoptotic cells [49–51]. Our findings indicate that splenic CD11hi
DCs (CD8a+ and CD82), but not pDCs, are targeted by i.v.
injection of apoptotic cells, which agrees with the previous findings
that splenic CD8a+ DCs are responsible for at least some of the
beneficial effects of apoptotic cell therapy [37,61].
Internalization of apoptotic cells down-regulates the T cell
stimulatory function of DCs by reducing their expression of MHC
and costimulatory molecules and secretion of pro-inflammatory
cytokines, while augmenting release of anti-inflammatory IL-10 and
TGF-b1 [23,26–31]. This is due to the presence on the apoptotic cell
surface of Apoptotic Cell Associated Molecular Patterns (ACAMPs),
which are recognized as ‘‘eat me’’ signals by pattern recognition
receptors on the surface of phagocytes during the assembly of the
phagocytic synapse [62]. The ACAMPs dock the apoptotic cell to
the phagocyte and deliver inhibitory signals to the APCs, that are
critical to prevent autoimmunity following apoptotic cell clearance of
self-tissues in physiological conditions. Therefore, apoptotic cells
constitute an ideal vehicle to deliver in situ simultaneously donor
allo-Ags and inhibitory signals to DCs of graft recipients, and thus
down-regulate indirect allorecognition. Our findings demonstrate
that DCs that have endocytosed donor apoptotic cells in vivo not
only retain a low ratio of co-stimulatory: inhibitory signals but also
resist ex vivo-maturation in response to DC-activating signals. Our
results also show that, unlike macrophages [63], those DCs affected
by the inhibitory effects of apoptotic cells do not exert bystander
effect on DCs that did not take up apoptotic cells.
Our study has addressed an important question for future
development of efficient apoptotic cell-based therapies for
promotion of transplantation tolerance: for how long recipient DCs
are able to present apoptotic cell-derived allopeptides to donor-reactive T cells
following systemic administration of donor apoptotic cells? Although splenic
DCs live between 1.5–2.9 days [64], indirect evidence indicates
they may present Ag for as long as 14 days [65]. This discrepancy
has been explained partly by the observation that proliferating
DCs prolong Ag presentation through passive transfer of long-
lived peptide-MHC complexes to daughter DCs [65,66]. Howev-
er, our finding that presentation of donor apoptotic cell-derived
allopeptides declines 3 days after apoptotic cell infusion indicates
that long-term presentation of donor allo-Ag for induction/
maintenance of transplant tolerance may require repetitive
administration of apoptotic cells.
We hypothesize that following in situ targeting with donor
apoptotic cells, recipient’s quiescent DCs of the spleen will present
the donor peptides in a pro-tolerogenic fashion due to the inhibitory
signals delivered by the apoptotic cells. However, in theory,
administration of donor splenocytes alive should exert a similar
effect, since the allogeneic cells will eventually die or become targets
of recipient’s NK cells. Surprisingly, numerous reports on the
immunosuppressive effects of apoptotic cells did not include living
cells as controls [21,39–41], and studies on the beneficial effects of
systemically administered donor splenocytes alive (donor specific
transfusion, DST) in transplantation did not compare their results
with controls injected with donor apoptotic splenocytes [67,68]. In
our model, although administration of donor splenocytes alive or
apoptotic triggered initial expansion of indirect CD4 T cells, only
apoptotic cell infusion was associated with deficient activation and
Figure 6. Impact of donor apoptotic splenocytes on lymphocyte infiltration and allo-Ab deposition in aortic grafts. Detection by
fluorescence microscopy of infiltrating CD4 and CD8 T cells, and IgG and C3d deposited in aortic BALB/c grafts, 60 days after transplant in syngeneic
(control) or B6 recipient mice, left untreated or injected with BALB/c splenocytes, apoptotic, necrotic, or alive. Cell nuclei were stained blue with DAPI.
Asterisks indicate the vessel lumen.6200.
doi:10.1371/journal.pone.0004940.g006
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Figure 7. Regulation of the systemic anti-donor response by donor apoptotic splenocytes. A) Assessment by IFN-c ELISPOT assay of the
indirect T cell response elicited in the spleens of B6 mice, naı¨ve (control), or transplanted 60 days before with syngeneic (control) or BALB/c aortic
grafts. Numbers indicate the number of spots. Each group included 4 mice. B) Detection by FACS of circulating alloAb in B6 recipients of syngeneic or
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deletion of indirect T cells. Interestingly, those T cells that escaped
deletion after apoptotic cell infusion exhibited reduced percentages
of IFN-c-secreting cells and increased numbers of IL-10-releasing
cells and FoxP3+, compared with controls treated with donor
splenocytes alive. These results agree with previous findings by us
[37] and others [69] that systemic administration of apoptotic cells
bearing allo-Ags or haptens is associated with generation/expansion
of donor- or hapten-specific Treg in mice. The regulatory effects of
donor apoptotic cells on indirect CD4 T cells explains their
therapeutic potential on CAV, since in murine and pig models,
CAV is initiated by CD4 T cells recognizing allo-Ag via the indirect
pathway [10–12,70].
Previous studies have shown that DST, particularly when
combined with CD40-CD40L (CD154) blockade, promotes
tolerance in cardiac allografts in mice [67,68]. However, in our
model and unlike donor apoptotic cell therapy, DST alone did not
prevent development of CAV. It has been proposed that a
generalized immune-suppressive effect results from the transfusion
to the recipient of a large number of phosphatidylserine bearing
cells, which through interaction with phosphatidylserine receptors
expressed by phagocytes results in down-regulation of the
stimulatory function of APCs [71]. Likely, in our system, the fact
that apoptotic cell death was synchronized by UVB-irradiation
and the apoptotic cells were administered as an i.v. bolus could
explain their potent immune-regulatory effect s in vivo. A similar
phenomenon could be the reason of the beneficial effects on
allograft rejection [72,73] and GVHD [74] of extracorporeal
photopheresis, a method that re-infuses elevated numbers of UV-
induced apoptotic PBMCs. Interestingly, tolerance associated to
therapy with depleting CD3 mAb is due to the regulatory effects
on APCs caused by a high number of apoptotic T cells generated
synchronically in vivo [75]. Unlike donor apoptotic cell therapy,
following DST: (i) generation of apoptotic cells in vivo is
asynchronic with slower kinetics and probably less inhibitory
potential on recipient APCs; and ii) recipient APCs may receive
CD40-mediated stimulation through CD154 expressed by trans-
fused allo-reactive CD4 T cells. The synergistic effect of CD40-
CD154 blockade on DST is likely due to (i) its pro-apoptotic effects
on adoptively transferred donor cells, since CD40-signalling
promotes survival of B lymphocytes and DCs; and (ii) blockade
of CD40-mediated activation of recipient DCs presenting donor
Ag acquired from the DST. Interestingly, both effects can be
achieved by simple administration of donor cells in early apoptosis.
Our results indicate that down-regulation of the indirect
alloresponse by donor apoptotic cell therapy prevents/ameliorates
CAV in aortic allografts, an established model of chronic rejection
elicited through the indirect pathway. Thus, development of CAV
in aortic grafts constituted an elegant model to investigate the
effect of donor apoptotic cell therapy on the indirect alloresponse.
Compared to alternative models of CAV in coronary arteries,
aortic grafts (i) facilitate the morphological analysis of the anti-
donor response within the vessels due to their bigger size, and (ii)
are not affected by the inflammation in the surrounding tissue, as
occurs in coronary arteries during cardiac allograft rejection.
Histologically, the artery allografts of animals treated with donor
apoptotic cells, did not have luminal occlusion and exhibited slight
intimal thickening with few a sm actin+ cells, no damage of elastic
fibers, substantially less collagen accumulation, and reduced T cell
infiltration. These beneficial effects on CAV were allo-specific and
dependent on the physical properties of the apoptotic bodies, since
administration of donor leukocytes alive or necrotic did not affect
the histological signs of CAV. Importantly, analysis of the indirect
allo-response 60 days post-transplant, confirmed that only those
animals treated with donor apoptotic cells exhibited reduced type-
1 T cell anti-donor responses and allo-Ab secretion.
Interestingly, our separate analysis of the direct and indirect
anti-donor responses in recipients treated with donor apoptotic
cells has revealed that the proposed model of the mechanism of
action of apoptotic cell therapy in transplantation hides an
important paradox: if donor apoptotic cells are required to be re-processed
by recipient APCs to down-regulate indirect pathway T cells, why donor
apoptotic cell therapy also reduces the anti-donor T cell response elicited through
the direct pathway? This phenomenon explains why apoptotic cell
therapy promotes heart allograft survival in murine models where
the direct pathway plays a dominant role in acute rejection
[37,38]. This paradoxical effect could be caused by: (i) interaction
of the donor apoptotic cells with direct pathway T cells or, more
likely, (ii) down-regulation of the indirect CD4 T cell help (through
T cell deletion or generation of Treg) required for maturation of
direct T cells into effector cells [76,77].
Development of novel methodologies to control the anti-donor T
cell response elicited through the indirect pathway represent an
effective strategy to ameliorate development of CAV and CR, the
major obstacles to the long-term success of solid organ transplan-
tation that the currently employed immunosuppressive drugs fail to
prevent. In situ-delivery of the entire repertoire of donor alloAg
along with a potent inhibitory signal to recipient’s DCs in secondary
lymphoid organs through donor-derived apoptotic bodies repre-
sents a novel, simple and relatively safe approach to down-regulate
the indirect alloresponse to achieve that goal.
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